Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Surgically Resectable Endometrial Carcinoma
NCT02630823Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2016
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in endometrial cancer (EC), sponsored by Washington University School of Medicine. Primary endpoints: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by >= 2 Patients and Safety as Measured by Any Grade 3 or Higher Treatment Related Adverse Events. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02630823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630823.